Results of the EA4151/BMT-CTN 1601 trial showed similar progression-free and overall outcomes with the addition of autologous transplant to rituximab in mantle cell lymphoma.
This multicenter cohort study develops and assesses the validity of a deep learning model for predicting immune checkpoint inhibitor response in patients with advanced non−small…
FDA Approval Alert brings together the most up-to-date information on the latest FDA approvals in oncology. On this page, read, watch, and listen to the…
Data from CheckMate-67T support the approval of subcutaneous nivolumab in patients with solid tumors across all previously approved nivolumab indications.
Chairs : Hermann Einsele, Maria Theresa Krauth, Maria Victoria Mateos, Omar Nadeem April 3-5, 2025 – Vienna, Austria Chairs: Hermann Einsele, Maria Theresa Krauth, Maria-Victoria…
Immunostaining for annexin A10 (ANXA10) and p53 was mainly negative in benign urothelium, ANXA10 expression was detected in low-grade urothelial carcinoma, and p53 expression was…
2024 was a year of breakthroughs in cancer care, research and knowledge at Ohio State, where oncology experts look ahead to opportunities to innovate in…
A humble mindset of the contributions he has made to genitourinary cancer care, Christopher J. Logothetis, MD, is also working to shape the next generation’s…
Two year grant of $130,000 for a postdoctoral or clinical research fellow to conduct research projects focused on hematologic malignancies.
Karen Lu, MD, is a nationally recognized physician-scientist who focuses her clinical and research interests on the surgical and medical treatment of women with ovarian…
European Medicines Agency recommends repotrectinib for ROS1-positive NSCLC; FDA approves therapies for NSCLC, LS-SCLC as well as a new diagnostic tool for identifying MET exon…
